AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT06657105
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Phase 4
Recruiting
- Conditions
- Chronic Lymphocytic LeukaemiaHeart Failure
- Interventions
- Other: Investigator's choice of treatment
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06651970
- Locations
- 🇬🇧
Research Site, Sutton Coldfield, United Kingdom
Covid-19 Data Analyses in Brazil
Completed
- Conditions
- Covid
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 361000
- Registration Number
- NCT06652451
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT06651021
- Locations
- 🇨🇳
Research Site, Chengdu, China
Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle
Recruiting
- Conditions
- COPD
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1368
- Registration Number
- NCT06646419
- Locations
- 🇨🇳
Research Site, Zaoyang, China
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Phase 2
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT06644924
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
Phase 1
Active, not recruiting
- Conditions
- Renal ImpairmentHeart Failure
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06639087
- Locations
- 🇧🇬
Research Site, Sofia, Bulgaria
Safety and Tolerability of AZD5148 in Japanese Participants
Phase 1
Active, not recruiting
- Conditions
- Clostridioides Difficile Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06639997
- Locations
- 🇯🇵
Research Site, Sumida-ku, Japan
VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain
Active, not recruiting
- Conditions
- Hyperkalaemia
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT06635499
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT06635447
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
© Copyright 2025. All Rights Reserved by MedPath